Analysts at StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Get Free Report) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Marinus Pharmaceuticals Trading Down 0.2 %
Marinus Pharmaceuticals stock opened at $0.55 on Wednesday. Marinus Pharmaceuticals has a 12-month low of $0.22 and a 12-month high of $9.41. The stock has a market cap of $30.32 million, a P/E ratio of -0.22 and a beta of 1.03. The company has a fifty day simple moving average of $0.55 and a 200-day simple moving average of $0.73.
Institutional Trading of Marinus Pharmaceuticals
Several institutional investors have recently modified their holdings of the stock. World Investment Advisors LLC purchased a new position in shares of Marinus Pharmaceuticals in the 3rd quarter valued at $104,000. Virtu Financial LLC purchased a new stake in shares of Marinus Pharmaceuticals in the 4th quarter valued at about $36,000. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in shares of Marinus Pharmaceuticals in the 4th quarter valued at about $54,000. JPMorgan Chase & Co. grew its stake in Marinus Pharmaceuticals by 1,968.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock worth $234,000 after buying an additional 126,752 shares during the last quarter. Finally, Deltec Asset Management LLC acquired a new position in Marinus Pharmaceuticals during the fourth quarter worth approximately $107,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Featured Stories
- Five stocks we like better than Marinus Pharmaceuticals
- 3 REITs to Buy and Hold for the Long Term
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- NVIDIA Insiders Sell: This Is What It Means for the Market
- Are Penny Stocks a Good Fit for Your Portfolio?
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
